Abeona Therapeutics (ABEO) stock gets a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. Read the full analysis here.
Global data from over 12,000 consumers signals the future of modern aesthetics will be multimodal treatment plans and holistic, natural results ...
With the singular exception of punctal or canalicular occlusion, when we are talking about in-office dry eye disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results